← Valneva overview

Valneva vs Eurofins Scientific: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Valneva SE (VLA.PA)

Q3 2026
▼2▲1

Lyme vaccine advances in Europe, but UK chikungunya setback and wider loss weigh

  • Lyme vaccine clears first European regulatory hurdle The EMA validated Pfizer and Valneva's application for their Lyme disease vaccine, starting the official review. If approved, it would be the first such vaccine in Europe and a major future revenue source for Valneva, which is the development partner. This is the biggest potential value driver in the period.

    This is the main positive force behind VLA.PA, a new regulatory milestone for its most advanced pipeline asset.

  • UK pulls chikungunya vaccine approval over safety UK regulators revoked the marketing authorization for Valneva's chikungunya vaccine Ixchiq, and the company will not appeal. Valneva says the financial hit is minimal, but losing a whole approved market removes a revenue stream and raises questions about the product's safety profile elsewhere.

    This is a new negative event that directly pressures VLA.PA shares and its commercial outlook.

  • First-half loss widens sharply on lower sales Valneva's net loss ballooned to €63.3 million from €20.8 million a year earlier, hurt by lower product sales, weak manufacturing volumes, and one-off costs including IXCHIQ contract termination and inventory write-offs. Cash rose to €121.5 million, and full-year guidance was kept, but profitability remains a concern.

    The widening loss and weak sales are a core fundamental drag on the stock, even as cash and guidance hold.

  • Lyme trial data strong but not statistically clean The Phase 3 VALOR trial showed over 70% efficacy, but the primary analysis narrowly missed its required statistical threshold, while a second analysis passed. This means approval is not guaranteed and the review could face scrutiny, tempering the optimism around the EMA filing.

    It is the key counterweight to the positive Lyme news, explaining why the regulatory win is not a sure thing.

September 2026
▼2▲1

Lyme vaccine advances in Europe, but UK chikungunya setback and wider loss weigh

  • Lyme vaccine clears first European regulatory hurdle The EMA validated Pfizer and Valneva's application for their Lyme disease vaccine, starting the official review. If approved, it would be the first such vaccine in Europe and a major future revenue source for Valneva, which is the development partner. This is the biggest potential value driver in the period.

    This is the main positive force behind VLA.PA, a new regulatory milestone for its most advanced pipeline asset.

  • UK pulls chikungunya vaccine approval over safety UK regulators revoked the marketing authorization for Valneva's chikungunya vaccine Ixchiq, and the company will not appeal. Valneva says the financial hit is minimal, but losing a whole approved market removes a revenue stream and raises questions about the product's safety profile elsewhere.

    This is a new negative event that directly pressures VLA.PA shares and its commercial outlook.

  • First-half loss widens sharply on lower sales Valneva's net loss ballooned to €63.3 million from €20.8 million a year earlier, hurt by lower product sales, weak manufacturing volumes, and one-off costs including IXCHIQ contract termination and inventory write-offs. Cash rose to €121.5 million, and full-year guidance was kept, but profitability remains a concern.

    The widening loss and weak sales are a core fundamental drag on the stock, even as cash and guidance hold.

  • Lyme trial data strong but not statistically clean The Phase 3 VALOR trial showed over 70% efficacy, but the primary analysis narrowly missed its required statistical threshold, while a second analysis passed. This means approval is not guaranteed and the review could face scrutiny, tempering the optimism around the EMA filing.

    It is the key counterweight to the positive Lyme news, explaining why the regulatory win is not a sure thing.

Latest
▼2▲1

Lyme vaccine advances in Europe, but UK chikungunya setback and wider loss weigh

  • Lyme vaccine clears first European regulatory hurdle The EMA validated Pfizer and Valneva's application for their Lyme disease vaccine, starting the official review. If approved, it would be the first such vaccine in Europe and a major future revenue source for Valneva, which is the development partner. This is the biggest potential value driver in the period.

    This is the main positive force behind VLA.PA, a new regulatory milestone for its most advanced pipeline asset.

  • UK pulls chikungunya vaccine approval over safety UK regulators revoked the marketing authorization for Valneva's chikungunya vaccine Ixchiq, and the company will not appeal. Valneva says the financial hit is minimal, but losing a whole approved market removes a revenue stream and raises questions about the product's safety profile elsewhere.

    This is a new negative event that directly pressures VLA.PA shares and its commercial outlook.

  • First-half loss widens sharply on lower sales Valneva's net loss ballooned to €63.3 million from €20.8 million a year earlier, hurt by lower product sales, weak manufacturing volumes, and one-off costs including IXCHIQ contract termination and inventory write-offs. Cash rose to €121.5 million, and full-year guidance was kept, but profitability remains a concern.

    The widening loss and weak sales are a core fundamental drag on the stock, even as cash and guidance hold.

  • Lyme trial data strong but not statistically clean The Phase 3 VALOR trial showed over 70% efficacy, but the primary analysis narrowly missed its required statistical threshold, while a second analysis passed. This means approval is not guaranteed and the review could face scrutiny, tempering the optimism around the EMA filing.

    It is the key counterweight to the positive Lyme news, explaining why the regulatory win is not a sure thing.

Eurofins Scientific SE (ERF.PA)

Q3 2026
▲4

Eurofins sharpens focus on life sciences with buybacks and deals

  • Strong first-half results and record cash conversion Eurofins reported 29% earnings-per-share growth, a record 47% cash conversion and EUR 200 million of share buybacks in the first half. Stronger profits and cash give the company more room to invest and return money to shareholders, which supports the shares.

    This is the period's core company result and the main fundamental driver of the stock.

  • Ongoing share buybacks support the stock Eurofins kept buying back its own shares through July and August, repurchasing 85,000 shares one week and 100,000 the next. Buybacks reduce the number of shares in circulation and signal management confidence, which tends to support the share price.

    Buybacks are a repeated but still active capital-return signal that helps explain price support.

  • Portfolio reshaped toward core life sciences testing Eurofins completed the EUR 575 million sale of its MET Labs electrical testing unit and the USD 400 million purchase of Element's North American life sciences business. It is swapping a non-core asset for 27 labs and over USD 150 million of annual revenue in a region where it was underrepresented.

    These two completed deals are the period's biggest strategic moves and directly affect future growth and capital allocation.

  • Growing market for preclinical cell-based testing A new report forecasts the preclinical cell-based assay services market to grow from about USD 4.5 billion in 2025 to USD 12.9 billion by 2035, with Eurofins named among the leading providers. A larger market gives Eurofins more room to win new testing work.

    This is the period's main demand-side signal for Eurofins' core testing business.

August 2026
▲4

Eurofins sharpens focus on life sciences with buybacks and deals

  • Strong first-half results and record cash conversion Eurofins reported 29% earnings-per-share growth, a record 47% cash conversion and EUR 200 million of share buybacks in the first half. Stronger profits and cash give the company more room to invest and return money to shareholders, which supports the shares.

    This is the period's core company result and the main fundamental driver of the stock.

  • Ongoing share buybacks support the stock Eurofins kept buying back its own shares through July and August, repurchasing 85,000 shares one week and 100,000 the next. Buybacks reduce the number of shares in circulation and signal management confidence, which tends to support the share price.

    Buybacks are a repeated but still active capital-return signal that helps explain price support.

  • Portfolio reshaped toward core life sciences testing Eurofins completed the EUR 575 million sale of its MET Labs electrical testing unit and the USD 400 million purchase of Element's North American life sciences business. It is swapping a non-core asset for 27 labs and over USD 150 million of annual revenue in a region where it was underrepresented.

    These two completed deals are the period's biggest strategic moves and directly affect future growth and capital allocation.

  • Growing market for preclinical cell-based testing A new report forecasts the preclinical cell-based assay services market to grow from about USD 4.5 billion in 2025 to USD 12.9 billion by 2035, with Eurofins named among the leading providers. A larger market gives Eurofins more room to win new testing work.

    This is the period's main demand-side signal for Eurofins' core testing business.

Latest
▲4

Eurofins sharpens focus on life sciences with buybacks and deals

  • Strong first-half results and record cash conversion Eurofins reported 29% earnings-per-share growth, a record 47% cash conversion and EUR 200 million of share buybacks in the first half. Stronger profits and cash give the company more room to invest and return money to shareholders, which supports the shares.

    This is the period's core company result and the main fundamental driver of the stock.

  • Ongoing share buybacks support the stock Eurofins kept buying back its own shares through July and August, repurchasing 85,000 shares one week and 100,000 the next. Buybacks reduce the number of shares in circulation and signal management confidence, which tends to support the share price.

    Buybacks are a repeated but still active capital-return signal that helps explain price support.

  • Portfolio reshaped toward core life sciences testing Eurofins completed the EUR 575 million sale of its MET Labs electrical testing unit and the USD 400 million purchase of Element's North American life sciences business. It is swapping a non-core asset for 27 labs and over USD 150 million of annual revenue in a region where it was underrepresented.

    These two completed deals are the period's biggest strategic moves and directly affect future growth and capital allocation.

  • Growing market for preclinical cell-based testing A new report forecasts the preclinical cell-based assay services market to grow from about USD 4.5 billion in 2025 to USD 12.9 billion by 2035, with Eurofins named among the leading providers. A larger market gives Eurofins more room to win new testing work.

    This is the period's main demand-side signal for Eurofins' core testing business.